One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

Figure 3 Rates of patients with hepatitis B e antigen loss and hepatitis B e antigen seroconversion, and alanine aminotransferase normalization through week 192. A: Percentage of patients with hepatitis B e antigen (HBeAg) loss in Groups A and B; B: Percentage of patients with HBeAg seroconversion in Groups A and B; C: Percentage of patients with alanine aminotransferase (ALT) normalization in Groups A and B in hepatitis B e antigen positive (+) patients; D: Percentage of patients with ALT normalization in Groups A and B in in HBeAg positive (+) patients. HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; ALT: Alanine transaminase.